Clinical Trial Update: Aleniglipron Phase 2 Body Composition Study [Phase 2]

View source ↗

Summary

Aleniglipron's Phase 2 body composition study in obesity-related conditions is active but not recruiting, sponsored by Gasherbrum Bio, Inc., a subsidiary of Str…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Aleniglipron (GSBR-1290)

Snippet

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Conditions: Obesity, Overweight, or Chronic Weight Management | Phase 2 | Status: ACTIVE_NOT_RECRUITING